



The Donaghue Foundation is a private trust that funds medical and health research.

Donaghue develops its grant programs and works with other organizations to help ensure that research findings are able to make meaningful contributions to health and health care policy and practice.



Greater Value Portfolio Research Spotlight

OPIOID ABUSE AND PHYSICIAN PRACTICE PATTERNS





This project examines an approach to changing prescribing practice for amedication with potential harm.

About This Project

At these year grant hat along \$49,100 was a warded to Arnol Novan the ,ND, PhD and Nitresh S. Pahel, ND, MBA of the University of Panneylvan lata conduct a prognatic, randomized, controlled that that will evaluate the effect of two behavioral economic approaches on changing approaches on the onlying physician apicial presenting.

91x365 At persent, drug overdose in the leading course of injury-elabed de drin the United States, with 91 Arm elections of lying from optical de lated overdoses each dray.

The Broblem

Physician behavior and presciption pathere have played a paticularly important to le in the genesis and acceleration of the opicid apidemic in the United States. Over the last has decades, the number of opicid prescriptions has quadrupled, and drug overdises deathed us to sever data on opicids have more than this led.

Of particular interest is the pill burden, that is, the number of days a prescription covers. The higher the pill burden in on individual opi did prescription, the mae likely it is that a patient will continue to use apolatis of an earnal three years. For example, a 5-day prescription leads to a 3-6-fa chance of continued use, while a 30-day prescription leads to a 20-35% chance of continued use. Physicians who are higher interestly apolating rescribes a sermore likely to have patients who use a pill did for larger ductions.



Percent Chance of Continued Use of Opiods

Project Approach


The trial will be conducted at 56 after thoughout Suffer Health System, to coping on new opioid prescriptions for higher volume, lower acculty conditions (e.g., acute joint sprains or back spasm) in emergency or urgent case settings.

+ Status Quo Bias

The is searches will evaluate the impact of setting distaut opicid prescription options in the electronic health record. This evaluation actions set what quo blow — the hendency to follow the path of least resistance, in particular selecting the delaut option in an BR.

+ Rel all ve Social Ranking

The researchers will evaluate the impact of providing social comparison free data on epicial prescribing behavior to physicians. This approach teverages the relative acciding in principle — the tendency for individuals to change behavior based on social norms and status.



ch You Prescribe MORE Pills Per Prescription Than valuate the incividual and combined Top Performers

+ Evaluation of Approach

The seasarchers will evaluate the individual and combined effect of these approaches and their impact or reducing acute pain.

+ Translating Research to Practice

The separchers propose to acide successful interventions across the entire network of the participatinghealth care system and to be acidy disseminate findings in an effort to hareform prescribing patterns for opioids nationwide.



The Health Research Alliance is a collaborative member organization of almost 80 nonprofit, nongovernmental funders.

HRA'S mission is to maximize the impact of our funding of biomedical research to improve human health.











Fondation





















american federation for aging research











Research Alliance













American Heart Association_®



Inspiring the Physician-Scientists of Tomorrow











Howard Hughes

Medical Institute

Templeton Foundation



Learn and Live





the compassion to care, the leadership to conquer











LEUKEMIA & LYMPHOMA SOCIETY fighting blood cancers

























American

Cancer

Society®





MT. SINAI





pcori





















Kenneth

Rainin



PERSHING SQUARE SOHN Cancer Research Alliance



American Society of Hematology











Katherine S. Rowell, M.S., M.H.A. Co-Founder & Principal

www.healthdataviz.com

kathy@healthdataviz.com

Now, tell us a bit about the work you do!

Quick Poll #1

HOUSEKEEPING

Lines are muted

Please type questions for Q& A at end of webinar in the box on the right hand side of your screen.

We will one more short poll and a quick survey at the end of this session (thank you for your participation—we greatly appreciate it!)

Downloads are available about the best practices of data visualization, and about today's sponsors.

Want to continue the conversation? Please drop us a note—we'd love to connect.

And, what you hope to learn during our time together.

Quick Poll #2




Health, Healthcare &
Statistics

Visual Intelligence &

Data Visualization

Technology

Technology



The Great American Novel


THE FUNDAMENTALS


VISUAL INTELLIGENCE & HUMAN COGNITION

RESEARCH & & EVIDENCE

INFORMS

BEST PRACTICES





Colin Ware

70% of the way we take in all data and information is through our eyes.



I See, I Understand


Count the Fives

See the Fives

Section 42 Row 37 Seat 21




Ted Williams... Longest home run ever hit into the Fenway bleachers







Overtime by Department




Overtime by Department




Overtime by Department










DRAFT Excellenc	e Every Day I	Dasht	ooard					
		CY10						
Priority Area	A ccounta bility	Q1	Q2	Q3	Q4			
Falls								
Patient Falls with Injury		0.46	0.45	0.41				
Serious Reportable Events		1	0	1	6			
Medical Records								
MD Notes Composite		72%	66%	65%	67%			
H&P Compliance		100%	96%	94%	95%			
H&P Updated per Policy		41%	21%	80%	45%			
Medication Management-Inpatient								
Medications Secured Properly		88%	83%	78%				
Expired Meds (Doses)		435	277					
Patients' Own Meds-Labelling		38%	86%	60%				
Recording/Reporting Fridge Temp		40%	70%	53%				
Patient Education on AntiCoag		80%						
Med Rec-Admission		89%	92%	89%	87%			
Med Rec-Discharge		98%	98%	98%	97%			
Medication Management-Outpatient								
Sites-MESAC Approval of Samples		100%	100%	100%				
Sites-Correct Use of SIMS for								
Approved Samples		86%	86%	86%				
Pain Management								
Pain Assessment/Reassessment		NA	97%	98%	98%			
Severe Pain Management		NA	84%	95%	97%			
Patient Identifiers								
Mislabeled Specimens		1058	1110	1177	1143			
Blood Transfusion RN Verification			Data i	TBD				
Safety Reporting Proxy		0	0	0	0			
Patient Rights								
Grievance Responded (per Hospital								
policy)		NA	79%	82%	76%			
Restraints								
Restraint Prevalence		NA	NA	6.1%	3.2%			
MD/NP/PA Daily Assessment		NA	NA	NA	33%			
Ordered per Policy		NA	90%	89%	89%			
Utilization Matches Order		NA	88%	80%	37%			
RN Assessment & Interventions		NA	92%	82%	85%			
Skin Integrity								
Pressure Ulcer Prevalence		NA	NA	2.9%	2.1%			
CNS Consults (>Stage 2)		NA	95%	87%				
Wound Measured Weekly		NA	86%	80%				
Serious Reportable Events		3	2	1	4			
Universal Protocol								
UP Compliance (Procedural Areas)		96%	99%	94%	92%			
UP Compliance (Ambulatory Areas)	1	71%	91%	64%	86%			
Wrong Site Procedures-SRE		0	2	0	1			
Other NP SGs								
Critical Value Callbacks		NA	NA	98%	98%			
Worry Box								
Interventions without Orders			Data 1	TBD				
Infection Control			Data					
Internal Handoffs			Data					
internal Handons	L		Data	.55				

		CY10				
Priority Area	Q1	Q2	Q3	Q4		
Falls						
Patient Falls with Injury	0.46	0.45	0.41			
Serious Reportable Events	1	0	1	6		
Medical Records						
MD Notes Composite	72%	66%	65%	67%		
H&P Compliance	100%	96%	94%	95%		
H&P Updated per Policy	41%	21%	80%	45%		
Medication Management-Inpatient						
Medications Secured Properly	88%	83%	78%	83%		
Patients' Own Meds-Labelling	38%	86%	60%	86%		
Recording/Reporting Fridge Temp	40%	70%	53%	83%		
Patient Education on AntiCoag	80%	80%	80%	80%		
Med Rec-Admission	89%	92%	89%	87%		
Med Rec-Discharge	98%	98%	98%	97%		
Medication Management-Outpatient				<u> </u>		
Sites-MESAC Approval of Samples	100%	100%	100%			
Sites-Correct Use of SIMS for						
Approved Samples	86%	86%	86%			
Pain Management						
Pain Assessment/Reassessment	NA	97%	98%	98%		
Severe Pain Management	NA	84%	95%	97%		
Patient Identifiers						
Mislabeled Specimens	1058	1110	1177	1143		
Blood Transfusion RN Verification		Data				
Safety Reporting Proxy	0	0	0	0		
Patient Rights						
Grievance Responded (per MGH						
policy)	NA	79%	82%	76%		
Restraints						
Restraint Prevalence	NA	NA	6.1%	3.2%		
MD/NP/PA Daily Assessment	NA	NA	NA	33%		
Ordered per Policy	NA	90%	89%	89%		
Utilization Matches Order	NA	88%	80%	37%		
RN Assessment & Interventions	NA	92%	82%	85%		
Skin Integrity						
Pressure Ulcer Prevalence	NA	NA	2.9%	2.1%		
CNS Consults (>Stage 2)	NA	95%	87%	2		
Wound Measured Weekly	NA	86%	80%			
Serious Reportable Events	3	2	1	4		
Universal Protocol						
UP Compliance (Procedural Areas)	96%	99%	94%	92%		
UP Compliance (Ambulatory Areas)	71%	91%	64%	86%		
Wrong Site Procedures-SRE	0	2	0470	1		
Other NPSGs	0					
Critical Value Callbacks	NA	NA	98%	98%		
MGH's Worry Box	14/4	IVA	30 /0	30 /0		
Interventions without Orders	Date TDD					
Infection Control	Data TBD Data TBD					
Internal Handoffs	Data TBD					
ппента панионя	Data IBD					

3-D or Not 3-D





Gestalt (Pattern) Principles

Proximity

Similarity

Enclosure

Closure


Continuity


Connection




Impact on Length of Stay

NEXT









F-Shaped Pattern For Reading Online Content

Summary: Eye tracking visualizations show that users often read online pages in an F-shaped pattern: two horizontal stripes followed by a vertical stripe.



www.useit.com

by JAKOB NIELSEN on April 17, 2006

Topics: **Eyetracking**

Tables

Use a TABLE to:

Look up individual values

Compare individual values

Display precise values

Communicate more than one unit of measure

Annual Monitoring for Patients on Persistent Medications - ACE Inhibitors or ARBs	86%	84%	81%	80%
Annual Monitoring for Patients on Persistent Medications - ACE Inhibitors or ARBs	85%	84%	81%	86%
Annual Monitoring for Patients on Persistent Medications - ACE Inhibitors or ARBs	85%	84%	81%	86%
Annual Monitoring for Patients on Persistent Medications - ACE Inhibitors or ARBs	84%	84%	81%	86%
Annual Monitoring for Patients on Persistent Medications - ACE Inhibitors or ARBs	84%	84%	81%	86%
Annual Monitoring for Patients on Persistent Medications - ACE Inhibitors or ARBs	81%	84%	81%	86%
	5%			
Annual Monitoring for Patients on Persistent Medications - Anticonvulsants	73%	89%	62%	71%
Annual Monitoring for Patients on Persistent Medications - Anticonvulsants	70%	60%	62%	71%
Annual Monitoring for Patients on Persistent Medications - Anticonvulsants	70%	89%	62%	71%
Annual Monitoring for Patients on Persistent Medications - Anticonvulsants	08%	89%	62%	71%
Annual Monitoring for Patients on Persistent Medications - Anticonvulsants	08%	09%	62%	71%
Annual Monitoring for Patients on Persistent Medications - Anticonvulsants	00%	89%	62%	71%
	6%			
Annual Monitoring for Patients on Persistent Medications - Diuretics	85%	84%	80%	80%
Annual Monitoring for Patients on Persistent Medications - Diuretics	84%	84%	80%	80%
Annual Monitoring for Patients on Persistent Medications - Diuretics	84%	84%	80%	86%

Annual Monitoring for Patients on Persistent Medications - Diuretics	83%	84%	80%	86%
Annual Monitoring for Patients on Persistent Medications - Diuretics	83%	84%	80%	86%
Annual Monitoring for Patients on Persistent Medications - Diuretics	81%	84%	80%	86%
	4%			
Annual Monitoring for Patients on Persistent Medications - Total rate	85%	83%	80%	85%
Annual Monitoring for Patients on Persistent Medications - Total rate	84%	83%	80%	85%
Annual Monitoring for Patients on Persistent Medications - Total rate	04%	83%	80%	85%
Annual Monitoring for Patients on Persistent Medications - Total rate	83%	83%	80%	85%
Annual Monitoring for Patients on Persistent Medications - Total rate	83%	83%	80%	85%
Annual Monitoring for Patients on Persistent Medications - Total rate	81%	83%	80%	85%
	4%			
Antidepressant Medication Management - Effective Acute Phase Treatment	71%	68%	63%	72%
Antidepressant Medication Management - Effective Acute Phase Treatment	69%	68%	63%	72%
Antidepressant Medication Management - Effective Acute Phase Treatment	68%	68%	63%	72%
Antidepressant Medication Management - Effective Acute Phase Treatment	68%	68%	63%	72%
Antidepressant Medication Management - Effective Acute Phase Treatment	00%	68%	63%	72%
Antidepressant Medication Management - Effective Acute Phase Treatment	04%	68%	63%	72%
- Total - Transc - Tr	6%			
Antidepressant Medication Management - Effective Continuation Phase Treatment	54%	52%	40%	55%
Antidepressant Medication Management - Effective Continuation Phase Treatment	54%	52%	40%	55%
Antidepressant Medication Management - Effective Continuation Phase Treatment	53%	52%	40%	55%

196	Antidepressant Medication Management - Effective Continuation Phase Treatment	52%	52%	40%	55%
	Antidepressant Medication Management - Effective Continuation Phase Treatment	50%	52%	40%	55%
7%	Antidepressant Medication Management - Effective Continuation Phase Treatment	48%	52%	40%	55%
196		7%			
\dashv					
196	Appropriate Testing for Children with Pharyngitis	93%	90%	77%	89%
5%	Appropriate Testing for Children with Phanyngitis	92%	90%	77%	89%
396					
596	Appropriate Testing for Children with Pharyngitis	92%	90%	77%	89%
5%	Appropriate Testing for Children with Phanyngitis	90%	90%	77%	80%
196					
\dashv	Appropriate Testing for Children with Pharyngitis	80%	90%	77%	89%
2%	Appropriate Testing for Children with Pharyngitis	83%	90%	77%	89%
2%		10%			
	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	97%	94%	84%	93%
2%	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	98%	94%	84%	93%
2%	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	90%	94%	84%	93%
1%	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	95%	94%	84%	93%
196	Appropriate Treatment for Children with Upper				
	Respiratory Infection (URI)	93%	94%	84%	93%
296	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	93%	94%	84%	93%
296		3%			
5%	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	30%	22%	24%	31%

Measure Name	Regional Rate	MA Rate	NCQA Nat Ave	NCQA 90th Percentile
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	20%	22%	24%	31%
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	21%	22%	24%	31%
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	21%	22%	24%	31%
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	21%	22%	24%	31%
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	20%	22%	24%	31%
	10%			
Breast Canoer Screening	84%	83%	71%	80%
Breast Cancer Screening	84%	83%	71%	80%
Breast Cancer Screening	83%	83%	7196	80%
Breast Cancer Screening	82%	83%	7196	80%
Breast Cancer Screening	82%	83%	7196	80%
Breast Cancer Screening	82%	83%	71%	80%
	2%			
Cervical Cancer Screening	80%	87%	77%	83%
Cervical Cancer Screening	87%	87%	77%	83%
Cervical Cancer Screening	87%	87%	77%	83%
Cervical Cancer Screening	88%	87%	77%	83%
Cervical Cancer Screening	87%	87%	77%	83%
Cervical Cancer Screening	83%	87%	77%	83%
	2%			
Chlamydia Screening in Women Ages 15 to 20	05%	57%	4196	52%
Chlamydia Screening in Women Ages 15 to 20	58%	57%	41%	52%
Chlamydia Screening in Women Ages 15 to 20	58%	57%	4196	52%
Chlamydia Screening in Women Ages 15 to 20	50%	57%	4196	52%
Chlamydia Screening in Women Ages 15 to 20	53%	57%	41%	52%
Chlamydia Screening in Women Ages 15 to 20	14%	57%	41%	52%
Chlamydia Screening in Women Ages 21 to 24	00%	62%	45%	50%
Chlamydia Screening in Women Ages 21 to 24	04%	62%	45%	59%
Chlamydia Screening in Women Ages 21 to 24	03%	62%	45%	59%
Chlamydia Screening in Women Ages 21 to 24	59%	62%	45%	59%

Chlamydia Screening in Women Ages 21 to 24	59%	62%	45%	59%
Chlamydia Screening in Women Ages 21 to 24	58%	62%	45%	59%
	8%			-
Cholesterol Management for Patients with Cardiovascular Conditions—LDL-C Screening	93%	92%	88%	93%
Cholesterol Management for Patients with Cardiovascular Conditions—LDL-C Screening	93%	92%	88%	93%
Cholesterol Management for Patients with Cardiovascular Conditions—LDL-C Screening	93%	92%	88%	93%
Cholesterol Management for Patients with Cardiovascular Conditions—LDL-C Screening	93%	92%	88%	93%
Cholesterol Management for Patients with Cardiovascular Conditions—LDL-C Screening	92%	92%	88%	939
Cholesterol Management for Patients with Cardiovascular Conditions—LDL-C Screening	88%	92%	88%	939
Colorectal Cancer Screening	82%	77%	61%	729
Colorectal Cancer Screening	78%	77%	61%	729
Colorectal Cancer Screening	78%	77%	6196	729
Colorectal Cancer Screening	78%	77%	61%	729
Colorectal Cancer Screening	75%	77%	61%	729
Colorectal Cancer Screening	71%	77%	61%	729
•	11%			
Comprehensive Diabetes Care - HbA1c Testing	95%	94%	89%	949
Comprehensive Diabetes Care - HbA1c Testing	94%	94%	89%	949
Comprehensive Diabetes Care - HbA1c Testing	94%	94%	89%	949
Comprehensive Diabetes Care - HbA1c Testing	94%	94%	89%	949
Comprehensive Diabetes Care - HbA1c Testing	93%	04%	89%	941
Comprehensive Diabetes Care - HbA1c Testing	93%	94%	89%	941
	3%			
Comprehensive Diabetes Care - LDL-C Screening	02%	01%	85%	911
Comprehensive Diabetes Care - LDL-C Screening	92%	91%	05%	911
Comprehensive Diabetes Care - LDL-C Screening	01%	01%	85%	919

Comprehensive Diabetes Care - LDL-C Screening	90%	91%	85%	91%
Comprehensive Diabetes Care - LDL-C Screening	89%	91%	85%	©1%
Comprehensive Diabetes Care - LDL-C Screening	87%	91%	85%	91%
Comprehensive Diabetes Care - Medical Attention for Nephropathy	91%	80%	83%	90%
Comprehensive Diabetes Care - Medical Attention for Nephropathy	90%	89%	83%	90%
Comprehensive Diabetes Care - Medical Attention for Nephropathy	90%	89%	83%	90%
Comprehensive Diabetes Care - Medical Attention for Nephropathy	89%	89%	83%	90%
Comprehensive Diabetes Care - Medical Attention for Nephropathy	89%	80%	83%	90%
Comprehensive Diabetes Care - Medical Attention for Nephropathy	80%	89%	83%	90%
	5%			
Follow-up of Care of Children Prescribed ADHD Medications - Initiation Phase	50%	45%	37%	45%
Follow-up of Care of Children Prescribed ADHD Medications - Initiation Phase	49%	45%	37%	45%
Follow-up of Care of Children Prescribed ADHD Medications - Initiation Phase	48%	45%	37%	45%
Follow-up of Care of Children Prescribed ADHD Medications - Initiation Phase	46%	45%	37%	45%
Follow-up of Care of Children Prescribed ADHD Medications - Initiation Phase	41%	45%	37%	45%
Follow-up of Care of Children Prescribed ADHD Medications - Initiation Phase	40%	45%	37%	45%
	9%			
Use of Appropriate Medications for People with Asthma: Children Ages 5 to 11	99%	97%	97%	99%

NCQA National Process Measures Example State Compliance Rates vs. National Compliance Rates @ 90th Percentile By Region

Region	Measure	Example State Rate	National Rate @ 90th Percentile	Variance
East	Appropriate Testing for Children with Pharyngitis	83%	90%	-7%
	Well Child Visits: Adolescents Ages 12 to 21	68%	74%	-6%
	Antidepressant Medication Mgmt: Acute Phase	64%	68%	-4%
	Antidepressant Medication Mgmt: Continuation Phase	48%	52%	-4%
	Followup Children Prescribed ADHD Medication: Initiation Phase	41%	45%	-4%
	Comprehensive Diabetes Care: Medical Neuropathy	86%	89%	-3%
West	Cholesterol Screening of Patients with Cardiovascular LDL	88%	92%	-4%
West	Comprehensive Diabetes Care: LD Screening	87%	91%	-4%
	Cervical Cancer Screening	83%	87%	-4%
	Monitoring Patients on ACE or ARB	81%	84%	-3%
	Monitoring Patients on Diuretics	81%	84%	-3%
South	Chlamydia Screening Women: Ages 21 to 24	59%	62%	-3%
	Followup Children Prescribed ADHD Medication: Initiation Phase	40%	45%	-5%
Metro	Chlamydia Screening Women: Ages 21 to 24	58%	62%	-4%
	Monitoring Patients on Anticonvulsants	66%	69%	-3%
North	Chlamydia Screening Women: Ages 21 to 24	58%	62%	-4%
	Well-Child Visits: Adolescents Ages 12 to 21	66%	69%	-3%





At-a-Glance


Use a GRAPH to:


Show Patterns


Show Trends


Show Exceptions


Reveal relationships between multiple values


















Measure Compliance

Provider	# Cases Eligbile for Measure Current Quarter	% Compliant Current Quarter	Difference (Under) Target		Quarterly Trend			
011-1-1	50		TARGET 70% 85%	75%	80%	70%	85%	
Clinician 6	50		05%	50%	60%	75%	80%	
Clinician 4	75		80%					
Clinician 1	65		80%	75%	50%	65%	80%	
Clinician 1	65		0076	45%	55%	40%	75%	
Clinician 5	35		75%					
Clinician 9	55	709	%	95%	95%	90%	70%	
Olinician 3	75	65%	-5%	50%	60%	55%	65%	
Clinician 2	35	60%	-10%	35%	45%	55%	60%	
Clinician 10	65	50%	-20%	50%	50%	50%	50%	
Clinician 7	50	45%	-25%	75%	80%	55%	45%	
Clinician 8	35	35%	-35%	25%	30%	30%	35	
		l		Q1	Q2	Q3	Q	



The Cholesterol Hunter.

Here's how he does it.

Quaker Outmeal isn't just a cholesterol-free.

food....it's a unique whole grain food that goes in and actually soaks up excess cholesterol and removes it from your body. So basically, you sit and enjoy a tasty bowl of oatmeal while it does its thing.


of the state of th

Not a bad deal, right?

It's hardworking.

Chalter Outmeal contains soluble fiber that actively finds the excess cholesterol, which can clog arteries and lead to heart disease, and binds with it. Your bloodstream can't

absorb the cholesterol, so it's removed from your body. This means you could see a drop in your overall number.





Need more proof?

Visit www.quakeroatmeal.com or call 1-800-770-4091.




By of exhibit filter delty these leatment (in a love seconded (in), low offselectric distributy reduce heart disease (six, Challer Cla Technised privation 3g per serving and Challer Instant Applies & Grountsin, Sprin privides 1 gaper serving.





All panels @ Harvard Business School, 2015, 2016.

Surgeon Comparison for Total Hip/Knee Replacement





State Diabetes Rates



State Diabetes Rates






Figure 4-2—NHHF Adult Medicaid CAHPS Results: Global Ratings




EXAMPLE (Not Actual Data) Example State Adult Medicaid CAHPS Results

2,500 State Medicaid Members Surveyed 23% Response Rate **27%** NCQA Survey Response Rate



EXAMPLE (Not Actual Data) Example State Adult Medicaid CAHPS Results

2,500 State Medicaid Members Surveyed 23% Response Rate




REQUIREMENTS GATHERING


SCOPE ROLE DECISIONS

Hospital CEO


YTD Performance: January 1 to December 31



MENTAL MODELS



GUIDED ANALYTICS



PROSTATE CANCER REGISTRY

Prostate Cancer Registry Overview





Copyright HealthDataViz -All Rights Reserved -- May not be distributed or reproduced without permission--2018

Prostate Cancer Registry Patient List




SEER Staging			cStage				pStage				
Distant Metastasis / Systemic Disease	Localized	Regional By Direct Extension	Regional By Extension And Nodes	2A	2B	3	4	2B	3	4	N/A
12	13	12	12	10	16	6	17	3	7	9	4

MON	CEER Comment Comme	-51		Type of First Recurrence	l C Sa	Gleason Score	Gleason Score	Vital Status
MRN 100035	SEER Summary Stage	cStage 2A	pStage UNK	No Recurrence	Last Cancer Status No Evidence of this cancer	(Biopsy)	(prostatectomy) No Resection	Alive
100035	Regional By Extension And Nodes	2A	4	No Recurrence	No Evidence of this cancer	7	7	Alive
							· · · · · · · · · · · · · · · · · · ·	
100230	Localized	2A	UNK	No Recurrence	No Evidence of this cancer	7	No Resection	Alive
100404	Regional By Direct Extension	2B	UNK	No Recurrence	No Evidence of this cancer	8	No Resection	Alive
100593	Regional By Direct Extension	2B	3	Recurrence, Site Unknown	Evidence of this cancer	9	UNK	Alive
100639	Regional By Extension And Nodes	2B	4	Null	Evidence of this cancer	8	7	Alive
100690	Distant Metastasis / Systemic Disease	4	4	Null	Evidence of this cancer	No Biopsy	No Resection	Dead
100917	Regional By Direct Extension	3	UNK	No Recurrence	No Evidence of this cancer	9	No Resection	Alive
101050	Regional By Extension And Nodes	2B	4	No Recurrence	No Evidence of this cancer	8	7	Alive
101124	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	7	No Resection	Dead
101191	Regional By Extension And Nodes	4	UNK	Null	Evidence of this cancer	9	No Resection	Alive
101271	Regional By Extension And Nodes	2B	4	No Recurrence	No Evidence of this cancer	8	7	Alive
101293	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	10	No Resection	Alive
101364	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	No Biopsy	No Resection	Alive
101494	Localized	2A	UNK	No Recurrence	No Evidence of this cancer	7	No Resection	Alive
101901	Regional By Extension And Nodes	3	N/A	Null	Evidence of this cancer	9	No Resection	Alive
101976	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	9	No Resection	Alive
102155	Localized	2B	2B	No Recurrence	No Evidence of this cancer	8	8	Alive
102430	Regional By Direct Extension	2B	3	No Recurrence	No Evidence of this cancer	9	7	Alive
102444	Distant Metastasis / Systemic Disease	4	N/A	Null	Evidence of this cancer	No Biopsy	No Resection	Alive
102866	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	9	No Resection	Alive
102971	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	9	No Resection	Alive
103034	Distant Metastasis / Systemic Disease	4	UNK	Null	Evidence of this cancer	8	No Resection	Alive
103056	Localized	2B	UNK	No Recurrence	No Evidence of this cancer	9	No Resection	Alive

Prostate Cancer Patient History Report





Copyright HealthDataViz -All Rights Reserved -- May not be distributed or reproduced without permission--2018

THERE IS NO SUCH THING AS INFORMATION OVERLOAD.

THERE IS ONLY BAD DESIGN.

EDWARD TUFTE

INFOGRAPHICS


NYC Data / Community Health Profiles

New York City Dynamic Community Health Profiles

About

The New York City Dynamic Community Health Profiles capture the health of 59 community districts across the city. The most comprehensive reports of neighborhood health ever produced, they look beyond traditional health measures to define a broader picture of neighborhood health including conditions such as housing quality, air pollution, and types of food accessible. Dynamic Community Health Profiles provide valuable information on significant health issues and can serve as a critical resource for improving health, community by community, and marks a step towards participatory public health.

Choose your community using the drop down menu below, then click on a section to view.






NYC | Queens | Jamaica and Hollis | Other Selected Community (Bronx: Morrisania and Crotona) | Most Favorable Rate

Obesity, diabetes and hypertension

Obesity can lead to diabetes, high blood pressure, and other health conditions. Hypertension, also known as high blood pressure, is a leading risk factor for heart disease and stroke. More than 700,000 adult New Yorkers have been told they have diabetes and an additional 164,000 are estimated to have diabetes but not be aware. **In Jamaica and Hollis:**

- **30%** of adults are obese, which is higher than NYC as a whole (the TCNY 2020 goal is to reduce the obesity rate to less than 23% citywide++)
- ▶ 16% of adults have been diagnosed with diabetes
- **37%** of adults have been told they have hypertension

Obesity, Diabetes and Hypertension (percent of adults)



Source: NYC DOHMH, Community Health Survey, 2015-2016

Housing and Neighborhood Conditions



Air Conditioners & Air Quality

Housing Quality

Bike Networks and Pedestrian Injury

Food Environment


New York City | Queens | Jamaica and Hollis | Other Selected Community (Bronx: Morrisania and Crotona) | Most Favorable Rate

The environment we live in makes it easier or more difficult to lead healthy lives.

Every resident has the right to live in housing that is safe and pest-free. Poorly maintained housing is associated with poor health outcomes, including worsened asthma and other respiratory illnesses.

In **Jamaica and Hollis**, **54%** of renter-occupied homes are adequately maintained – free from heating breakdowns, cracks, holes, peeling paint and other defects...

Homes With No Maintenance Defects (percent of renter-occupied homes)



Source: NYC Housing and Vacancy Survey, 2014

A final word about our team.

Founded in 2013 By and For Health & Healthcare Professionals

VISUAL INTELLIGENCE EXPERTS

DEEP HEALTH & HEALTHCARE EXPERIENCE & EXPERTISE


RECOGNIZED TABLEAU CERTIFIED EXPERTS


USER EXPERIENCE (UE) & USER INTERFACE (UI) PROFICIENCY








OUR BOOKS














Questions?

One last thing!

Help us out by answering a quick survey when the Webinar ends – THANKS!.

